

How to efficiently update non-compliant Early Development trial to meet submission requirements

Qianqian Cheng / Principal Statistical Programming Lead

2025-08-29





How to efficiently update non-compliant Early Development trial to meet submission requirements

Presented by Qianqian Cheng, C&SP, Johnson&Johnson



Meet the Speaker

Qianqian Cheng

Title: Statistical Programming Lead

Organization: Janssen China R&D, Johnson & Johnson

Qianqian Cheng graduated from Fudan University in 2012. She had worked as Statistical programmer at Pfizer for more than 4 years. She Joined Johnson & Johnson as Oncology TA statistical programmer lead in 2017, and supported the approval of Darzalex clinical study in Multiple Myeloma and Amyloidosis, and CARVYTI in Multiple Myeloma Due-Diligence, NMPA submission, inspection and approval. Currently, she focuses on two CAR-T clinical studies in Lymphoma.



Disclaimer and Disclosures

- *The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the views or policies of Johnson & Johnson.*
- *The author(s) have no real or apparent conflicts of interest to report.*
- *The data analysis in this presentation is based on dummy data, with no real data involved. The results are for illustrative purposes only and have no practical significance.*



Agenda

1. Background
2. Challenges & Solutions & Case Sharing
3. Summary



Background

- Features of Early Development (ED)
- Background of Clinical Trial




Features of Early Development (ED)

- Short (relatively short project timelines)
- Frequent (high delivery frequency)
- Fast (tight schedules)



Background of Overall Clinical Trial

- **Indication:** CAR-T Study in Lymphoma
- **Primary Endpoint:** Safety + RP2D (Recommended Phase2 Dose)
- **Milestone:** Supported 2 SET Meetings (1 SET/3Month)
- **Analysis Scope:** 5 ADaMs + 20~TFLs
- **Potential Plan:** Link with Phase2 Study
- **Resource:** Limited



Challenges & Solutions & Case Sharing

Challenges & Solutions 01 - Data

➤ Challenge :

- ADaMs Metadata: missing label for variables
- Variable Name is non-compliant
- ADaMs Structure/purpose

➤ Solution :



- Analysis Drive : SAP/TFLs purpose to Metadata
- Change the variable name based on CDISC guideline
- Remove unnecessary ADaM

Case Sharing


➤ Variable Name is non-compliant:

- Original Name:

- CAR-T infusion: TRTS1SDT/TRTS1EDT (Safety baseline)
- Lymphodepletion: TRTO1SDT/ TRTO1EDT, TRTO2SDT/ TRTO2EDT (Efficacy baseline)

- CDISC ADaM IG:

2. The lower case letters “w”, “xx”, “y”, and “zz” that appear in a variable name or label in this document must be replaced in the actual variable name or label using the following conventions.
 - a. The lower-case letter “w” in a variable name (e.g., PHwSDT, PxxSwSDT) is an index for the wth variable where “w” is replaced with a single digit [1-9].
 - b. The letters “xx” in a variable name (e.g., TRTxxP, APxxSDT) refer to a specific period where “xx” is replaced with a zero-padded two-digit integer [01-99]. The use of ‘xx’ within a variable name is restricted to the concept of a period.



Case Sharing

- P21 Validation Report:

| Pinnacle 21 Enterprise Validation Report | | | | | | |
|--|----------|------------------------|--------------|--|-------|-------|
| Dataset | Values | Rule ID | Publisher ID | Message | FDA | PMDA |
| ADSL | TRRCSDT | AD1019 | + | Illegal variable name: xx is not in [01-99] for an ADSL trial date | Error | Error |
| ADSL | TRCAEDTM | AD1019 | + | Illegal variable name: xx is not in [01-99] for an ADSL trial date | Error | Error |
| ADSL | TRCAEDT | AD1019 | + | Illegal variable name: xx is not in [01-99] for an ADSL trial date | Error | Error |
| ADSL | TRCASDTM | AD1019 | + | Illegal variable name: xx is not in [01-99] for an ADSL trial date | Error | Error |
| ADSL | TRCASDT | AD1019 | + | Illegal variable name: xx is not in [01-99] for an ADSL trial date | Error | Error |

- Updated Name:

| Variable Name | Label |
|---------------|-----------------------------|
| CTRTSDT | CAR-T Start Date |
| CTRTEDT | CAR-T End Date |
| FLTRTSDT | Fludarabine Start Date |
| FLTRTEDT | Fludarabine End Date |
| CYTRTSDT | Cyclophosphamide Start Date |
| CYTRTEDT | Cyclophosphamide End Date |

Challenges & Solutions 02 - Code

➤ Challenge :

- Code is not organized - Difficult to understand and update
- A lot of derivation rules are in TFL program
- QC code is not in tracker

➤ Solution :

- Set up program/macro conventions
- Re-organize all programs/macros – readable
- Derivation code in TFLs -> ADaMs parameter
- QC code should be promoted for tracker



```

line name desc=10 First therapy (Event) START
Vndbf7(desc=ad11)

#####
Corrected No. of First Therapy Lines CPULINES
Vndbf7(desc=ad11, out=desc=ad11)

#####
Lymphoma E Response
Vndfjgmpy(desc=ad11)

#####
Induction DelayED (number of days delay) Second lymphoblastim Re-performed after Delay (ED)
Vndbf7(desc=ad11)

#####
Begin start date of ALLBONE12 records
Vndbf7(desc=ad11)

#####
Best response to First line therapy PHILRES
Relapse at 9070 month after the initiation of 1st line therapy PHILREP
Vndfjgacnc(desc=ad11)

#####
Derive start date of Lymphoblastim records
Vndfjgndep(desc=ad11)

#####
relapst Relapsatory or relapsed disease to last line of prior therapies
Vndfjgpl(desc=ad11)

#####
P0004 prior systemic therapies received within the first 2 years response
Vndf26f(desc=ad11)

#####
CR30 Response in 30 months PLTP
Vndbf70(desc=ad11)

```

Challenges & Solutions 03

➤ Challenge :

- Early Development Study may have many run-in groups/exploratory subgroup analysis based on diff indications

➤ Solution : = Efficient + Smart work

- Insert the flexible button in TFLs program
- Add the flags in ADSL
- Centralize to control the TFL Layout
- Set up the TFL programs convention

Case Sharing

➤ Insert the flexible button in TFLs program:

Scenario 01:

```
.....  
%macro trtgroup(DSN);  
  data &DSN.;  
    set &DSN.;  
    if trt01an in (1,2) then _COLVAR = 1;  
    else if trt01an in (3,4,5,6) then _COLVAR = 2;  
    else if trt01an in (7,8,9,10,11,12) then _COLVAR = 3;  
  
  run;  
  
%mend trtgroup;
```

Call this macro in TFLs program

Scenario 02:

```
%macro trtgroup(DSN);  
  data _adsl;  
    set a_in.adsl;  
    where FUD26FL="Y";  
    keep usubjid;  
    proc sort; by usubjid;  
  run;  
  
  data _dsn;  
    set &DSN.;  
    proc sort; by usubjid;  
  run;  
  
  data _dsn01;  
    merge _adsl(in=a) _dsn;  
    by usubjid;  
    if a;  
  run;  
  
  data &DSN.;  
    set _dsn01;  
    if trt01an in (1,2) then _COLVAR = 1;  
    else if trt01an in (3,4,5,6) then _COLVAR = 2;  
    else if trt01an in (7,8,9,10) then _COLVAR = 3;  
    else if trt01an in (11,12) then _COLVAR = 4;  
  run;  
  
%mend trtgroup;
```



```
options validvarname =uppercase mprint nomlogic nosymbolgen;
```

```
%trtgroup(dsn = adsl);  
%trtgroup(dsn = slae);
```

Challenges & Solutions 04

➤ Challenge :

- Phase1b link with Phase2
- Phase1b+Phase2 in one database **VS** phase1b/2 diff in some CRF pages
- Phase1b and Phase2: Diff TFL Layout

➤ Solution :

- Attend CRF Setup/review Meeting
- Evaluate the potential update to impact SDTM structure
- Evaluate the potential ADaMs update based on updated SDTM structure
- Efficiently produce the Phase1b/2 TFLs

Case Sharing

- 1 set of programs are built up
- Use the Replace App to update program by batch
- 3 potential Sets programs: xxxPH1, XXXPH2,XXXRP2D



Summary

Proactive evaluate potential risk from submission, set up Database/code conventions in study start-up

- Programming Lead should have the big/whole picture from startup to Submission, from study to compound(pooled analysis)
- Empower/inspire supporting programmers
- Set up the regular programming meeting (Follow-up/Timely-update)
- Set up the compound programming conventions (keep the compound consistent)



Thank You!

